Recent News

• 10.22.2026 - Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
• 10.01.2026 - Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
• 09.30.2026 - Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
• 08.24.2026 - Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
• 08.21.2026 - Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
• 08.12.2026 - Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• 07.16.2026 - Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
• 05.13.2026 - Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
• 04.15.2026 - Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
• 03.23.2026 - Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Recent Filings

• 10.22.2026 - EX-99.1 EX-99.1
• 10.22.2026 - 8-K Current report
• 10.07.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 10.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.01.2026 - SC TO-I/A Tender offer statement by Issuer